BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...a small molecule inhibitor of LSD1 to treat myeloproliferative neoplasms. Plunkett was CFO at Nkarta Inc. (NASDAQ:NKTX).miRagen Therapeutics Inc....
...to bring its advanced program in Fabry disease closer to approval. Escolar was CMO at miRagen.Ann...
...Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...Jackson, who was VP of research for miRagen Therapeutics Inc....
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...ester (SHAPE), remetinostat (shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...and obstructive sleep apnea. Citrine launched with an $80 million series A round in July. Investors back miRagen-Viridian...
...Logos Capital, Citadel's Surveyor Capital, Commodore Capital, and Ridgeback Capital in the round. The deal follows miRagen’s...
...to $83 million in milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Elpis Galecto Inc. Citrine Medicine Bioprojet miRagen CASI...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...Acer, Kala NDAs before funding lapse” ). Servier returns MRG-110 rights as miRagen trims staff miRagen Therapeutics Inc....
...Servier (Neuilly-sur-Seine, France) has discontinued development of MRG-110, returning rights to the microRNA therapeutic to miRagen...
...penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen Therapeutics Inc. MicroRNA-29...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...acting CFO Manfred Groppel, who remains COO. Seymour was CFO of Signal Genetics Inc. (now miRagen Therapeutics Inc....
BioCentury | May 11, 2018
Finance

Amplifying oligos

...industry,” said Marett. Moving past microaggressions Despite early interest in miRNA, partnerships have leveled off. miRagen Therapeutics Inc....
...CEO William Marshall told BioCentury miRNA had a spike in deal flow in 2011, including miRagen’s...
...what you think in humans as soon as you can,” said Marshall. He told BioCentury miRagen...
BioCentury | Feb 23, 2018
Financial News

miRagen raises $38.5M in follow-on

...MicroRNA company miRagen Therapeutics Inc. (NASDAQ:MGEN) raised $38.5 million on Feb. 8 through the sale of 7 million...
...close of $8.60 on Feb. 2, before the offering was proposed. miRagen Therapeutics Inc. (NASDAQ:MGEN), Boulder, Colo. Shannon Lehnbeuter miRagen Therapeutics Inc....
BioCentury | Oct 21, 2017
Product Development

Naked ambition

...Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous...
...and a long half-life without the addition of a conjugate or vehicle. On Oct. 13, miRagen...
...in the molecule, what you’ll find is you get more serum protein binding.” William Marshall, miRagen...
BioCentury | Oct 20, 2017
Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

...Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting in London. miRagen...
...report longer-term dosing data at the American Society of Hematology meeting in Atlanta in December. miRagen...
...a systemic anti-microRNA therapy in oncology. MRG-106 is a synthetic microRNA antagonist of microRNA-155 (miR-155). miRagen...
Items per page:
1 - 10 of 78
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...a small molecule inhibitor of LSD1 to treat myeloproliferative neoplasms. Plunkett was CFO at Nkarta Inc. (NASDAQ:NKTX).miRagen Therapeutics Inc....
...to bring its advanced program in Fabry disease closer to approval. Escolar was CMO at miRagen.Ann...
...Pharma Inc. (NASDAQ:XLRN).TARGETSFASN (FAS) – Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea...
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...Jackson, who was VP of research for miRagen Therapeutics Inc....
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...ester (SHAPE), remetinostat (shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...and obstructive sleep apnea. Citrine launched with an $80 million series A round in July. Investors back miRagen-Viridian...
...Logos Capital, Citadel's Surveyor Capital, Commodore Capital, and Ridgeback Capital in the round. The deal follows miRagen’s...
...to $83 million in milestones plus tiered royalties. BC Staff Ultragenyx Pharmaceutical Inc. Scholar Rock Holding Corp. Elpis Galecto Inc. Citrine Medicine Bioprojet miRagen CASI...
BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...Acer, Kala NDAs before funding lapse” ). Servier returns MRG-110 rights as miRagen trims staff miRagen Therapeutics Inc....
...Servier (Neuilly-sur-Seine, France) has discontinued development of MRG-110, returning rights to the microRNA therapeutic to miRagen...
...penetrating particle (KPI-121) MRG-110 (S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen Therapeutics Inc. MicroRNA-29...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...acting CFO Manfred Groppel, who remains COO. Seymour was CFO of Signal Genetics Inc. (now miRagen Therapeutics Inc....
BioCentury | May 11, 2018
Finance

Amplifying oligos

...industry,” said Marett. Moving past microaggressions Despite early interest in miRNA, partnerships have leveled off. miRagen Therapeutics Inc....
...CEO William Marshall told BioCentury miRNA had a spike in deal flow in 2011, including miRagen’s...
...what you think in humans as soon as you can,” said Marshall. He told BioCentury miRagen...
BioCentury | Feb 23, 2018
Financial News

miRagen raises $38.5M in follow-on

...MicroRNA company miRagen Therapeutics Inc. (NASDAQ:MGEN) raised $38.5 million on Feb. 8 through the sale of 7 million...
...close of $8.60 on Feb. 2, before the offering was proposed. miRagen Therapeutics Inc. (NASDAQ:MGEN), Boulder, Colo. Shannon Lehnbeuter miRagen Therapeutics Inc....
BioCentury | Oct 21, 2017
Product Development

Naked ambition

...Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous...
...and a long half-life without the addition of a conjugate or vehicle. On Oct. 13, miRagen...
...in the molecule, what you’ll find is you get more serum protein binding.” William Marshall, miRagen...
BioCentury | Oct 20, 2017
Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

...Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting in London. miRagen...
...report longer-term dosing data at the American Society of Hematology meeting in Atlanta in December. miRagen...
...a systemic anti-microRNA therapy in oncology. MRG-106 is a synthetic microRNA antagonist of microRNA-155 (miR-155). miRagen...
Items per page:
1 - 10 of 78